Insulet Launches Enhanced Omnipod 5 Algorithm for Diabetes Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
Insulet Corp's stock rose by 5.08% as it crossed above the 5-day SMA, reflecting positive investor sentiment following the launch of an enhanced algorithm for the Omnipod 5. The new algorithm introduces a 100 mg/dL target glucose option, allowing users to manage diabetes more personally and improving time in range while reducing hypoglycemia risk. Additionally, the Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor, enhancing user convenience and promoting the adoption of automated insulin delivery, which is expected to significantly improve patient quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 143.520
Low
316.00
Averages
375.83
High
450.00
Current: 143.520
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insulet Reports Promising Clinical Trial Results for Next-Gen Insulin Delivery Systems
- Clinical Trial Results: Insulet presented promising clinical trial results for its next-generation tubeless Automated Insulin Delivery systems at the American Diabetes Association's 86th Scientific Sessions, with the STRIVE trial demonstrating strong glycemic control and the ability to deliver up to 50% more automated insulin, significantly reducing the need for manual boluses across various age groups and diabetes types.
- Closed-Loop System Study: The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system for type 2 diabetes, designed to automatically adjust insulin levels without requiring manual user settings, thereby simplifying clinical workflows and removing traditional barriers to care.
- Alignment with Innovation Strategy: These technological advancements align with Insulet's broader innovation strategy that prioritizes technology requiring less daily effort from users while improving health outcomes, indicating the company's commitment to making diabetes management more automated and accessible.
- Market Potential Outlook: While Insulet is recognized as a stock with investment potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's diverse focus on different technology sectors and investment opportunities.
See More
Insulet's Omnipod 6 Shows Strong Clinical Outcomes in Diabetes Management
- STRIVE Trial Results: The STRIVE pivotal trial involved 132 participants with HbA1c levels of 6.9% for type 1 and 7.3% for type 2 diabetes, demonstrating significant glycemic control improvements with Omnipod 6, particularly showing 54% of time in the 70-140 mg/dL range for type 1 diabetes, a 7-point increase over Omnipod 5, indicating its potential in diabetes management.
- EVOLUTION 3 Study Findings: The EVOLUTION 3 study revealed that the fully closed-loop system for type 2 diabetes maintained 64% time in range while reducing daily insulin from 86 units to 58 units without weight gain, showcasing its effectiveness in enhancing patient quality of life.
- Enhanced User Experience: In the EVOLUTION 3 study, 86% of participants reported satisfaction or high satisfaction with the fully closed-loop system, indicating that the technology not only achieved clinical success but also significantly reduced the burden of diabetes management, facilitating clinical adoption.
- Future Research Directions: Insulet plans to further evaluate Omnipod 6 in the upcoming STRIVE 2 study among patients who bolus fewer than four times daily and do not meet HbA1c clinical targets, demonstrating the company's commitment to ongoing innovation and improved diabetes management.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
Competitive Analysis of Diabetes Monitoring Market
- DexCom Financial Performance: In FY 2025, DexCom achieved nearly $4.7 billion in revenue, a 15.6% increase, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Position: Insulet generated over $2.7 billion in revenue in FY 2025, representing a 30.9% growth, with a net income of about $354.4 million and a net margin close to 10.4%, demonstrating its leadership and market expansion capabilities in the tubeless insulin pump sector.
- Competitive Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating a March 2025 FDA warning letter, which could impact its market performance, while Insulet's reliance on a single Omnipod product platform exposes it to risks from shifts in consumer preferences.
- Future Growth Potential: Despite the rise of GLP-1 drugs potentially affecting demand for both companies' products, the ongoing need for diabetes monitoring and treatment remains strong, with both DexCom and Insulet seeking to leverage technological innovation and market expansion to capture future growth opportunities.
See More
Comparative Analysis of Diabetes Management Innovations
- DexCom Financial Performance: In FY 2025, DexCom reported nearly $4.7 billion in revenue, a 15.6% increase year-over-year, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Expansion: Insulet achieved over $2.7 billion in revenue for FY 2025, representing a 30.9% growth rate, with a net income of about $354.4 million, demonstrating robust demand for its products despite fierce competition in the medical technology sector.
- Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating an FDA warning letter that could impact its market position; meanwhile, Insulet's reliance on its single Omnipod product makes it vulnerable to losing partnerships with DexCom, which would impair product functionality.
- Valuation Comparison: Insulet's forward P/E ratio stands at 22.0x, lower than DexCom's 28.4x, and its P/S ratio is 3.6x, indicating a more attractive investment value, especially given the significant upside potential in the automated treatment device market.
See More
Insulet Launches Enhanced Omnipod 5 Algorithm to Improve Diabetes Management
- Algorithm Upgrade: Insulet has launched a new algorithm for the Omnipod 5 in the U.S., introducing a 100 mg/dL target glucose option that allows users to manage diabetes more personally, thereby improving time in range (TIR) and reducing hypoglycemia risk.
- Sensor Compatibility: The Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor, enabling users to monitor through the LibreLinkup app, enhancing flexibility and convenience in diabetes management and further promoting the adoption of automated insulin delivery.
- Market Impact: This update aims to help users spend less time making decisions about diabetes management, enhancing user confidence and control, and is expected to significantly improve patient quality of life while reducing healthcare burdens.
- Future Outlook: Insulet plans to share more information at the 2026 American Diabetes Association Scientific Sessions, further promoting the international rollout of Omnipod 5 and showcasing its innovative leadership in diabetes management.
See More
Insulet Reports Promising Clinical Trial Results for Next-Gen Insulin Delivery Systems
- Clinical Trial Results: Insulet presented promising clinical trial results for its next-generation tubeless Automated Insulin Delivery systems at the American Diabetes Association's 86th Scientific Sessions, with the STRIVE trial demonstrating strong glycemic control and the ability to deliver up to 50% more automated insulin, significantly reducing the need for manual boluses across various age groups and diabetes types.
- Closed-Loop System Study: The company also shared findings from the EVOLUTION 3 feasibility study, which focused on a fully closed-loop system for type 2 diabetes, designed to automatically adjust insulin levels without requiring manual user settings, thereby simplifying clinical workflows and removing traditional barriers to care.
- Alignment with Innovation Strategy: These technological advancements align with Insulet's broader innovation strategy that prioritizes technology requiring less daily effort from users while improving health outcomes, indicating the company's commitment to making diabetes management more automated and accessible.
- Market Potential Outlook: While Insulet is recognized as a stock with investment potential, analysts note that certain AI stocks may offer greater upside potential and lower downside risk, reflecting the market's diverse focus on different technology sectors and investment opportunities.
See More
Insulet's Omnipod 6 Shows Strong Clinical Outcomes in Diabetes Management
- STRIVE Trial Results: The STRIVE pivotal trial involved 132 participants with HbA1c levels of 6.9% for type 1 and 7.3% for type 2 diabetes, demonstrating significant glycemic control improvements with Omnipod 6, particularly showing 54% of time in the 70-140 mg/dL range for type 1 diabetes, a 7-point increase over Omnipod 5, indicating its potential in diabetes management.
- EVOLUTION 3 Study Findings: The EVOLUTION 3 study revealed that the fully closed-loop system for type 2 diabetes maintained 64% time in range while reducing daily insulin from 86 units to 58 units without weight gain, showcasing its effectiveness in enhancing patient quality of life.
- Enhanced User Experience: In the EVOLUTION 3 study, 86% of participants reported satisfaction or high satisfaction with the fully closed-loop system, indicating that the technology not only achieved clinical success but also significantly reduced the burden of diabetes management, facilitating clinical adoption.
- Future Research Directions: Insulet plans to further evaluate Omnipod 6 in the upcoming STRIVE 2 study among patients who bolus fewer than four times daily and do not meet HbA1c clinical targets, demonstrating the company's commitment to ongoing innovation and improved diabetes management.
See More
Quantum Stocks Decline While Consumer Staples Rise
- Quantum Stocks Struggle: Quantinuum's debut on Nasdaq was lackluster, closing flat and subsequently dropping over 8% on Friday, falling below its IPO price of $60 per share, indicating market caution towards the quantum computing sector which may impact future funding and investor confidence.
- Consumer Staples Surge: Amid Friday's market sell-off, the consumer staples sector rose 2%, with companies like Colgate-Palmolive, Coca-Cola, and Procter & Gamble gaining over 3%, reflecting investor preference for defensive stocks, which could lead to a shift in capital towards these stable industries.
- Strong Performance in Medical Devices: Cooper Companies reported second-quarter adjusted earnings of $1.21 per share, exceeding the $1.10 consensus estimate, with revenue of $1.08 billion surpassing the $1.05 billion forecast, showcasing robust performance in the medical device sector that may attract more investor interest.
- Software Stocks Outlook Weakens: Docusign's outlook failed to impress, with shares slipping 6% as it projected second-quarter revenue between $865 million and $869 million, slightly below consensus, potentially affecting its future market performance and investor confidence.
See More
Competitive Analysis of Diabetes Monitoring Market
- DexCom Financial Performance: In FY 2025, DexCom achieved nearly $4.7 billion in revenue, a 15.6% increase, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Position: Insulet generated over $2.7 billion in revenue in FY 2025, representing a 30.9% growth, with a net income of about $354.4 million and a net margin close to 10.4%, demonstrating its leadership and market expansion capabilities in the tubeless insulin pump sector.
- Competitive Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating a March 2025 FDA warning letter, which could impact its market performance, while Insulet's reliance on a single Omnipod product platform exposes it to risks from shifts in consumer preferences.
- Future Growth Potential: Despite the rise of GLP-1 drugs potentially affecting demand for both companies' products, the ongoing need for diabetes monitoring and treatment remains strong, with both DexCom and Insulet seeking to leverage technological innovation and market expansion to capture future growth opportunities.
See More
Comparative Analysis of Diabetes Management Innovations
- DexCom Financial Performance: In FY 2025, DexCom reported nearly $4.7 billion in revenue, a 15.6% increase year-over-year, with a net income of approximately $836.3 million and a net margin of 17.9%, indicating strong growth potential in the continuous glucose monitoring market.
- Insulet Market Expansion: Insulet achieved over $2.7 billion in revenue for FY 2025, representing a 30.9% growth rate, with a net income of about $354.4 million, demonstrating robust demand for its products despite fierce competition in the medical technology sector.
- Risk Analysis: DexCom faces intense competition from large medical technology firms and is navigating an FDA warning letter that could impact its market position; meanwhile, Insulet's reliance on its single Omnipod product makes it vulnerable to losing partnerships with DexCom, which would impair product functionality.
- Valuation Comparison: Insulet's forward P/E ratio stands at 22.0x, lower than DexCom's 28.4x, and its P/S ratio is 3.6x, indicating a more attractive investment value, especially given the significant upside potential in the automated treatment device market.
See More
Insulet Launches Enhanced Omnipod 5 Algorithm to Improve Diabetes Management
- Algorithm Upgrade: Insulet has launched a new algorithm for the Omnipod 5 in the U.S., introducing a 100 mg/dL target glucose option that allows users to manage diabetes more personally, thereby improving time in range (TIR) and reducing hypoglycemia risk.
- Sensor Compatibility: The Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor, enabling users to monitor through the LibreLinkup app, enhancing flexibility and convenience in diabetes management and further promoting the adoption of automated insulin delivery.
- Market Impact: This update aims to help users spend less time making decisions about diabetes management, enhancing user confidence and control, and is expected to significantly improve patient quality of life while reducing healthcare burdens.
- Future Outlook: Insulet plans to share more information at the 2026 American Diabetes Association Scientific Sessions, further promoting the international rollout of Omnipod 5 and showcasing its innovative leadership in diabetes management.
See More
